Aptamer-based multiplexed proteomic technology for biomarker discovery

BACKGROUND The interrogation of proteomes ("proteomics") in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine. METHODOLOGY/PRINCIPAL FINDINGS We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 µL of serum or plasma). Our current assay measures 813 proteins with low limits of detection (1 pM median), 7 logs of overall dynamic range (~100 fM-1 µM), and 5% median coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding signature of DNA aptamer concentrations, which is quantified on a DNA microarray. Our assay takes advantage of the dual nature of aptamers as both folded protein-binding entities with defined shapes and unique nucleotide sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to rapidly discover unique protein signatures characteristic of various disease states. CONCLUSIONS/SIGNIFICANCE We describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.

[1]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[2]  E. Petricoin,et al.  Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle , 2010, Clinical Proteomics.

[3]  Dan Schneider,et al.  Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.

[4]  Jerzy Silberring,et al.  Biomarker discovery and clinical proteomics. , 2010, Trends in analytical chemistry : TRAC.

[5]  Samy I McFarlane,et al.  The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease , 2010, Current diabetes reports.

[6]  Michael P. Cusack,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[7]  Robert E. Kearney,et al.  A HUPO test sample study reveals common problems in mass spectrometry-based proteomics , 2009, Nature Methods.

[8]  Ruedi Aebersold,et al.  A stress test for mass spectrometry–based proteomics , 2009, Nature Methods.

[9]  Ruedi Aebersold,et al.  Mass spectrometry based targeted protein quantification: methods and applications. , 2009, Journal of proteome research.

[10]  R. Service.  Proteomics Ponders Prime Time , 2008, Science.

[11]  골드 래리,et al.  Method for generating aptamers with improved off-rates , 2008 .

[12]  R. Vanholder,et al.  The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? , 2008, Journal of nephrology.

[13]  Larry Gold,et al.  Proteomics and diagnostics: Let's Get Specific, again. , 2008, Current opinion in chemical biology.

[14]  C. Borrebaeck,et al.  High-throughput proteomics using antibody microarrays: an update , 2007, Expert review of molecular diagnostics.

[15]  Michael Famulok,et al.  Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. , 2007, Chemical reviews.

[16]  Neil R. Powe,et al.  Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. , 2007, Kidney international.

[17]  L. Ferrucci,et al.  Magnitude of Underascertainment of Impaired Kidney Function in Older Adults with Normal Serum Creatinine , 2007, Journal of the American Geriatrics Society.

[18]  Hanlee P. Ji,et al.  Multiplexed protein detection by proximity ligation for cancer biomarker validation , 2007, Nature Methods.

[19]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[20]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[21]  Sheila A Doggrell,et al.  Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration , 2005, Expert opinion on pharmacotherapy.

[22]  Bengt Rippe,et al.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. , 2005, American journal of physiology. Renal physiology.

[23]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[24]  Jonathan D. Vaught,et al.  T7 RNA polymerase transcription with 5-position modified UTP derivatives. , 2004, Journal of the American Chemical Society.

[25]  B. Eaton,et al.  RNA-Mediated Metal-Metal Bond Formation in the Synthesis of Hexagonal Palladium Nanoparticles , 2004, Science.

[26]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[27]  R. Beavis,et al.  A method for reducing the time required to match protein sequences with tandem mass spectra. , 2003, Rapid communications in mass spectrometry : RCM.

[28]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[29]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[30]  S. Kingsmore,et al.  Multiplexed protein profiling on microarrays by rolling-circle amplification , 2002, Nature Biotechnology.

[31]  L. Gold,et al.  Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.

[32]  R. Zietse,et al.  TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. , 2000, Clinical nephrology.

[33]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[34]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[35]  T. Tarasow,et al.  RNA-catalysed carbon–carbon bond formation , 1997, Nature.

[36]  B. Eaton,et al.  The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. , 1997, Current opinion in chemical biology.

[37]  B. Eaton,et al.  New Uridine Derivatives for Systematic Evolution of RNA Ligands by Exponential Enrichment , 1995 .

[38]  L. Gold,et al.  Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.

[39]  A. Pardi,et al.  High-resolution molecular discrimination by RNA. , 1994, Science.

[40]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[41]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[42]  J. Volanakis,et al.  Metabolism of complement factor D in renal failure. , 1988, Kidney international.

[43]  J. Ninio.  Kinetic amplification of enzyme discrimination. , 1975, Biochimie.

[44]  J. Hopfield.  Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Peter Mitchell,et al.  Proteomics retrenches , 2010, Nature Biotechnology.